Compare · DFTX vs OBIO
DFTX vs OBIO
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Orchestra BioMed Holdings Inc. (OBIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and OBIO operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.00B, about 16.4x OBIO ($244.3M).
- DFTX has been more active in the news (21 items in the past 4 weeks vs 7 for OBIO).
- OBIO has more recent analyst coverage (9 ratings vs 5 for DFTX).
- Company
- Definium Therapeutics Inc.
- Orchestra BioMed Holdings Inc.
- Price
- $38.02+3.65%
- $4.06+0.00%
- Market cap
- $4.00B
- $244.3M
- 1M return
- +67.92%
- -
- 1Y return
- +473.91%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 21
- 7
- Recent ratings
- 5
- 9
Latest DFTX
- Needham reiterated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics, Inc. Announces Proposed Public Offering
- SEC Form 424B5 filed by Definium Therapeutics Inc.
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 24% to 513,317 units (SEC Form 4)
- Chief Executive Officer Barrow Robert was granted 375,000 shares, increasing direct ownership by 50% to 1,127,454 units (SEC Form 4)
- Chief Legal Officer Sullivan Mark was granted 62,500 shares, increasing direct ownership by 23% to 333,579 units (SEC Form 4)
- Chief Financial Officer Roberts Brandi was granted 62,500 shares, increasing direct ownership by 42% to 212,500 units (SEC Form 4)
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 54% to 177,500 units (SEC Form 4)
- Definium Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
Latest OBIO
- Sidoti Events, LLC's June Small-Cap Virtual Conference
- Chief Financial Officer Taylor Andrew Lawrence covered exercise/tax liability with 36,352 shares, decreasing direct ownership by 6% to 593,065 units (SEC Form 4) to satisfy tax liability
- Officer Hochman David P covered exercise/tax liability with 6,566 shares, decreasing direct ownership by 0.31% to 1,060,746 units (SEC Form 4) (tax withholding)
- Officer Hochman David P bought $19,150 worth of shares (5,000 units at $3.83), increasing direct ownership by 0.47% to 1,064,029 units (SEC Form 4)
- Officer Sherman Darren sold $58,050 worth of shares (15,000 units at $3.87) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,184,327 units (SEC Form 4)
- Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 144 filed by Orchestra BioMed Holdings Inc.
- Chief Financial Officer Taylor Andrew Lawrence covered exercise/tax liability with 3,076 shares, decreasing direct ownership by 0.49% to 629,417 units (SEC Form 4) (for tax liability)
- Officer Sherman Darren covered exercise/tax liability with 4,925 shares, decreasing direct ownership by 0.41% to 1,199,327 units (SEC Form 4) to satisfy tax liability
- Director Aryeh Jason bought $2,494 worth of shares (665 units at $3.75), increasing direct ownership by 0.57% to 118,118 units (SEC Form 4)